MA50394A - Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques - Google Patents

Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques

Info

Publication number
MA50394A
MA50394A MA050394A MA50394A MA50394A MA 50394 A MA50394 A MA 50394A MA 050394 A MA050394 A MA 050394A MA 50394 A MA50394 A MA 50394A MA 50394 A MA50394 A MA 50394A
Authority
MA
Morocco
Prior art keywords
active substances
manufacturing processes
receptor agonist
pharmaceutical formulations
opioid receptor
Prior art date
Application number
MA050394A
Other languages
English (en)
Inventor
Grazia Caivano
Borges Ana Filipa Silva
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA50394A publication Critical patent/MA50394A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050394A 2017-10-20 2018-10-17 Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques MA50394A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17197466 2017-10-20

Publications (1)

Publication Number Publication Date
MA50394A true MA50394A (fr) 2021-04-28

Family

ID=60191117

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050394A MA50394A (fr) 2017-10-20 2018-10-17 Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques

Country Status (10)

Country Link
US (2) US10660849B2 (fr)
EP (1) EP3697381B1 (fr)
JP (1) JP7378391B2 (fr)
KR (1) KR102660711B1 (fr)
CN (1) CN111246841A (fr)
BR (1) BR112020007808A2 (fr)
CA (1) CA3077627A1 (fr)
MA (1) MA50394A (fr)
MX (1) MX2020003697A (fr)
WO (1) WO2019076997A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020124073A1 (fr) * 2018-12-14 2020-06-18 Pear Therapeutics, Inc. Composant thérapeutique numérique pour optimiser l'induction de produits contenant de la buprénorphine
BR112021019901A2 (pt) * 2019-04-18 2022-02-15 Chiesi Farm Spa Método para tratar síndrome de abstinência neonatal devido à retirada de opioides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8533582A (en) * 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US5601077A (en) * 1991-08-07 1997-02-11 Becton, Dickinson And Company Nasal syringe sprayer with removable dose limiting structure
GB9823246D0 (en) * 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
DE10084709T1 (de) * 1999-06-16 2002-09-26 Nastech Pharm Co Pharmazeutische Formulierung und Verfahren, die intranasales Morphin umfassen
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
NZ568313A (en) * 2005-11-21 2011-11-25 Schering Plough Ltd Pharmaceutical compositions comprising buprenorphine
GB2461681A (en) * 2008-04-17 2010-01-13 Pharmasol Ltd Buprenorphine liquid spray formulation with solvent and antioxidant
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
HRP20211539T1 (hr) * 2011-09-19 2021-12-24 Orexo Ab Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
US9034401B1 (en) * 2014-01-23 2015-05-19 Matrixx Initiatives, Inc. Pharmaceutical compositions comprising plant extracts and methods for reducing duration of a common cold using same
WO2016105563A1 (fr) * 2014-12-23 2016-06-30 Arx, Llc Procédé de production de formulations uniformes contenant de la buprénorphine

Also Published As

Publication number Publication date
EP3697381B1 (fr) 2023-06-07
RU2020115819A (ru) 2021-11-23
US10660849B2 (en) 2020-05-26
JP7378391B2 (ja) 2023-11-13
WO2019076997A1 (fr) 2019-04-25
KR20200073223A (ko) 2020-06-23
US20200237650A1 (en) 2020-07-30
CN111246841A (zh) 2020-06-05
RU2020115819A3 (fr) 2021-11-23
JP2020537682A (ja) 2020-12-24
CA3077627A1 (fr) 2019-04-25
EP3697381A1 (fr) 2020-08-26
MX2020003697A (es) 2020-08-13
BR112020007808A2 (pt) 2020-10-20
KR102660711B1 (ko) 2024-04-26
US20190117556A1 (en) 2019-04-25
EP3697381C0 (fr) 2023-06-07

Similar Documents

Publication Publication Date Title
MA41937A (fr) Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
FR2949062B1 (fr) Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
DOP2017000306A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
MA46867A (fr) Formulations pharmaceutiques
MA50189A (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2008002479A1 (es) Composicion farmaceutica que comprende: a) una o mas sustancias medicamentosas, b) un lipido, c) un co-lipido y d) un mejorador de flujo; formulacion en polvo seco; procesos de elaboracion.
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
MA49977A (fr) Combinaisons pharmaceutiques comprenant un anticorps anti-ly75
MA52174A (fr) Anticorps dirigés contre le récepteur 1 des chimiokines et leurs utilisations thérapeutiques
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
MA55015A (fr) Formulations pharmaceutiques
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA50394A (fr) Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques
MA41326A (fr) Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
FR2984750B1 (fr) Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
EP3539978A4 (fr) Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif
MA45718A (fr) Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
MA54095A (fr) Formulations pharmaceutiques aqueuses
MA44859A (fr) Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
MA53812A (fr) Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
MA51826A (fr) Compositions pharmaceutiques comprenant de la teixobactine